A timeline of events and released industry communications regarding Baycol provides evidence that Bayer not only suppressed its own clinical trial data, but also ignored it and continued to market Baycol and submit applications to FDA for the approval of Baycol at higher doses (0.4mg, 0.8mg). Bayer ignored the FDA's warning letters, which stated that Bayer's promotional material was "false, lacking in fair balance, or otherwise misleading", and similarly ignored patients' adverse events reports after using Baycol. Baycol was recalled in the US on August 8, 2001.
Have a look at the timeline that shows Bayer's attempts to ignore and suppress the risk of harm from rhabdomyolysis at lower doses of Baycol, while still submitting applications to FDA for approval of higher doses of Baycol.
Both Canadian and American Baycol-users are pursuing lawsuits against Baycol's maker.